Pharmaceutical TechnologyOriginal article
Bristol Myers Squibb secures expanded US approval for Camzyos
RegulatoryapprovedCamzyosPositive
AI Analysis
Summary
Bristol Myers Squibb received FDA approval to expand Camzyos' indication to treat symptomatic oHCM in both adult and pediatric patients weighing at least 30 kg, broadening the drug's market potential.
Outcome Details
FDA expanded approved indication for Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg
Importance:7/10
Sentiment:
0.80
FDA approvalindication expansionpediatric approvaloHCM
Related Companies
Read the original article
Published by Pharmaceutical Technology on October 1, 2026 9:21 AM